Table 3. Outcome after UDLI for 12... | American Society of Hematology

Table 3.

Outcome after UDLI for 12 patients treated for early-phase relapse of CML

Disease Status at IDLI	No.	MNC Dose × 10⁸/kg	Response and Outcome
Molecular relapse	2	0.05-0.23	No response; both patients remain PCR⁺ for bcr/abl 10-71 weeks after UDLI.
Cytogenetic relapse	4	0.4-1.0	4/4 complete responses (2 patients tested with PCR had no evidence of disease).
			2 remain alive in CR 34 and 79 weeks after DLI; 2 died from complications of GVHD.
Chronic-phase relapse	6	0.4-3.9	3/6 complete responses, and 2 remain alive. Of 3 nonresponders, 2 died of progressive disease, and 1 remains in CR after second BMT.

Disease Status at IDLI	No.	MNC Dose × 10⁸/kg	Response and Outcome
Molecular relapse	2	0.05-0.23	No response; both patients remain PCR⁺ for bcr/abl 10-71 weeks after UDLI.
Cytogenetic relapse	4	0.4-1.0	4/4 complete responses (2 patients tested with PCR had no evidence of disease).
			2 remain alive in CR 34 and 79 weeks after DLI; 2 died from complications of GVHD.
Chronic-phase relapse	6	0.4-3.9	3/6 complete responses, and 2 remain alive. Of 3 nonresponders, 2 died of progressive disease, and 1 remains in CR after second BMT.